HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment. The clearance followed a successful ...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...
A 68-year-old man without previous comorbidities presented to the emergency department with complaints of palpitations and giddiness. On examination, his pulse rate was 92 beats per minute, and his ...
Company engaging in multiple options for a constructive resolution Strategy is underpinned by a clinical study that achieved the agreed upon endpoints Company believes that labeling modifications can ...
This will enable the Company to efficiently validate real-world performance of the HeartBeam System and establish reference sites. "Bryan is an exceptional commercial leader with the experience and ...
DiaCardia, a novel artificial intelligence model that can accurately identify individuals with prediabetes using either 12-lead or single-lead electrocardiogram (ECG) data, has been developed. This ...
An investigation has found a "concerning level of variation" in how 12-lead electrocardiogram (ECG) skills are taught in UK undergraduate paramedic programmes. A report by the Health Services Safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results